166 related articles for article (PubMed ID: 32700459)
1. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
[TBL] [Abstract][Full Text] [Related]
5. Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics
.
Adedoyin A; Cho CR; Fox-Bosetti S; Macha S; Zhao T; Liu F; Panebianco D; O'Reilly TE; McCrea J; Stoch SA; Iwamoto M
Int J Clin Pharmacol Ther; 2019 Sep; 57(9):450-457. PubMed ID: 31232280
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients.
Prohn M; Viberg A; Zhang D; Dykstra K; Davis C; Macha S; Sabato P; de Alwis D; Iwamoto M; Fancourt C; Cho CR
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):255-267. PubMed ID: 33440077
[TBL] [Abstract][Full Text] [Related]
9. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial.
Erb-Zohar K; Kropeit D; Scheuenpflug J; Stobernack HP; Hulskotte E; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
Clin Transl Sci; 2017 Nov; 10(6):487-495. PubMed ID: 28675594
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
Scheuenpflug J; Kropeit D; Erb-Zohar K; Theis JGW; Stobernack HP; McCormick D; Zimmermann H; Rübsamen-Schaeff H
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):6-15. PubMed ID: 34812580
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the inhibitory effects of itraconazole on letermovir.
McCrea JB; Menzel K; Fancourt C; Witter R; Zhao T; Robbins JA; Stoch SA; Iwamoto M
Br J Clin Pharmacol; 2023 Jul; 89(7):2122-2130. PubMed ID: 36717270
[TBL] [Abstract][Full Text] [Related]
14. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
[TBL] [Abstract][Full Text] [Related]
16. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects.
Kropeit D; McCormick D; Erb-Zohar K; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):16-24. PubMed ID: 34714967
[TBL] [Abstract][Full Text] [Related]
19. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
